TRACON Pharmaceuticals (TCON) is all set to receive a $3 million milestone payment from its partner Santen Pharmaceutical Co., following the filing of an Investigational New Drug Application with the FDA for the initiation of clinical studies for DE-122 in patients with wet AMD.